Your browser doesn't support javascript.
loading
Venoarterial extracorporeal membrane oxygenation for cardiogenic shock and cardiac arrest: a meta-analysis.
Xie, Ashleigh; Phan, Kevin; Tsai, Yi-Chin; Yan, Tristan D; Forrest, Paul.
Afiliação
  • Xie A; The Collaborative Research (CORE) Group, Macquarie University, Sydney, Australia; University of New South Wales, Sydney, Australia.
  • Phan K; The Collaborative Research (CORE) Group, Macquarie University, Sydney, Australia; University of New South Wales, Sydney, Australia.
  • Tsai YC; Department of Cardiothoracic Surgery, Prince Charles Hospital, Brisbane, Australia.
  • Yan TD; The Collaborative Research (CORE) Group, Macquarie University, Sydney, Australia; Department of Cardiothoracic Surgery; University of Sydney, Sydney, Australia. Electronic address: tristanyan@annalscts.com.
  • Forrest P; Cardiothoracic Anesthesia and Perfusion, Royal Prince Alfred Hospital, Sydney, Australia; University of Sydney, Sydney, Australia.
J Cardiothorac Vasc Anesth ; 29(3): 637-45, 2015.
Article em En | MEDLINE | ID: mdl-25543217
OBJECTIVE: To evaluate the effect of extracorporeal membrane oxygenation (ECMO) on survival and complication rates in adults with refractory cardiogenic shock or cardiac arrest. DESIGN: Meta-analysis. SETTING: University hospitals. PARTICIPANTS: One thousand one hundred ninety-nine patients from 22 observational studies. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Observational studies published from the year 2000 onwards, examining at least 10 adult patients who received ECMO for refractory cardiogenic shock or cardiac arrest were included. Pooled estimates with 95% confidence intervals were calculated based on the Freeman-Tukey double-arcsine transformation and DerSimonian-Laird random-effect model. Survival to discharge was 40.2% (95% confidence intervals [CI], 33.9-46.7), while survival at 3, 6, and 12 months was 55.9% (95% CI, 41.5-69.8), 47.6% (95% CI, 25.4-70.2), and 54.4% (95% CI, 36.6-71.7), respectively. Survival up to 30 days was higher in cardiogenic shock patients (52.5%, 95% CI, 43.7%-61.2%) compared to cardiac arrest (36.2%, 95% CI, 23.1%-50.4%). Concurrently, complication rates were particularly substantial for neurologic deficits (13.3%, 95% CI, 8.3-19.3), infection (25.1%, 95%CI, 15.9-35.5), and renal impairment (47.4%, 95% CI, 30.2-64.9). Significant heterogeneity was detected, although its levels were similar to previous meta-analyses that only examined short-term survival to discharge. CONCLUSIONS: Venoarterial ECMO can improve short-term survival in adults with refractory cardiogenic shock or cardiac arrest. It also may provide favorable long-term survival at up to 3 years postdischarge. However, ECMO also is associated with significant complication rates, which must be incorporated into the risk-benefit analysis when considering treatment. These findings require confirmation by large, adequately controlled and standardized trials with long-term follow-up.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Choque Cardiogênico / Oxigenação por Membrana Extracorpórea / Parada Cardíaca Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Revista: J Cardiothorac Vasc Anesth Assunto da revista: ANESTESIOLOGIA / CARDIOLOGIA Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Choque Cardiogênico / Oxigenação por Membrana Extracorpórea / Parada Cardíaca Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Revista: J Cardiothorac Vasc Anesth Assunto da revista: ANESTESIOLOGIA / CARDIOLOGIA Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Austrália